Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
Biogen and Dayra announced a research collaboration to discover and optimize oral macrocyclic peptides for immunological targets. Dayra receives $50 million upfront and may receive candidate-acquisition payments and development milestones per program. Biogen would lead subsequent development, manufacturing, and potential commercialization. The agreement concerns early discovery rather than established clinical efficacy.
Sungening reported that its preclinical SG6001 oral cyclic peptide program for hyperlipidemia was included in Shenzhen’s strategic emerging industries support initiative for innovative drug technology. The announcement did not disclose an award amount or human results. Program support advances research resources rather than establishing clinical authorization, product approval, or completed commercial manufacturing.
Merck presented Phase 3 CORALreef HeFH results in adults with heterozygous familial hypercholesterolemia receiving background lipid-lowering therapy. Enlicitide reduced LDL-C by 59.4% versus placebo at week 24 and 61.5% at week 52. The overall safety profile was comparable with placebo. The study evaluated lipid changes rather than cardiovascular-event outcomes.
Merck reported Phase 3 CORALreef Lipids results showing a 55.8% placebo-adjusted LDL-C reduction at week 24 in the primary analysis. A post hoc reanalysis addressing biologically implausible baseline values estimated 59.7%. LDL-C reductions persisted through week 52. These lipid findings should not be equated with demonstrated reductions in cardiovascular events.
HitGen researchers describe a method for synthesizing DNA-encoded bicyclic peptides using cysteine-promoted cyclization and amide condensation under mild conditions. The abstract reports compatibility with varied sequences and ring sizes. This is discovery-platform chemistry, not evidence that the resulting peptides have oral exposure, clinical efficacy, or validated manufacturing-scale performance.
FDA approved oral linaclotide for irritable bowel syndrome with constipation in children ages 7 and older. Evidence included extrapolation from adult studies and a 12-week randomized pediatric trial. This gut-acting, disulfide-constrained peptide is not an example of high systemic oral absorption. Diarrhea remains an important adverse reaction, and use in children younger than 2 is contraindicated.
This study characterized indomethacin–nicotinamide cocrystals using MicroED together with solid-state NMR, Raman spectroscopy, and powder X-ray diffraction. MicroED supplied the crystal structure, while NMR helped examine molecular interactions. The combined approach addressed properties that individual methods could not establish alone, offering a pharmaceutical cocrystal workflow relevant to API powders and formulations containing excipients.
AbbVie announced completion of its Capstan acquisition on August 19, 2025, adding a targeted LNP platform for RNA delivery and in vivo cell engineering. This historical ownership event explains the company relationship. Candidate-stage descriptions in that release should be read at their original date, not as a current trial update.
This standards article examines lessons from the growing body of refined MicroED structures and accessible diffraction data. It discusses quality indicators and proposes community best practices for assessing and reporting results. The recommendations provide a framework for critical evaluation rather than regulatory certification or a guarantee that every structure meets the same quality threshold.
In the randomized phase 3 VERITAC-2 trial, vepdegestrant improved progression-free survival versus fulvestrant in the ESR1-mutated subgroup, but not significantly in the overall population. The trial enrolled 624 patients with previously treated ER-positive, HER2-negative advanced breast cancer. Grade 3 or higher adverse events occurred more often with vepdegestrant.
This review examines RNA species, structure and function, chemical modifications, and delivery systems in the context of therapeutic development. It connects molecular design with stability and distribution and discusses clinical applications available at the time of writing. Its historical approval overview should not be interpreted as a current, exhaustive drug list.
The study examined API crystals directly in Allegra, Clarith, and Ibrance tablets using selected-area 3D ED/MicroED. Fexofenadine hydrochloride Form I and clarithromycin Form II retained their polymorphs, while palbociclib Form A showed slight lattice shrinkage. The results demonstrate formulation-level structural analysis and emphasize that a lattice change and a new polymorph are different findings.
Continue your research
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
